Tesamorelin in Canada: Research Guide (2026)

For laboratory research use only. Nothing on this page is medical advice, and no compound discussed here is offered for human use. Tesamorelin is not currently marketed as an authorised drug in Canada.

What is tesamorelin?

Tesamorelin is a stabilized analog of growth-hormone-releasing hormone (GHRH 1-44). Native GHRH is degraded quickly in circulation; tesamorelin carries a trans-3-hexenoyl modification at its N-terminus that slows that degradation, which is what made it a viable pharmaceutical candidate and, later, a heavily studied research compound. Mechanistically it is studied as an agonist at pituitary GHRH receptors — the receptor pathway that regulates endogenous growth-hormone release — which places it in the GHRH-analog class alongside sermorelin and CJC-1295, and distinguishes it from ghrelin-receptor secretagogues such as ipamorelin.

Two things make tesamorelin unusual among research peptides. First, it has the deepest human clinical literature in its class: it is the active ingredient in EGRIFTA, a prescription drug approved by the FDA in the United States for one narrow indication under medical supervision. Second, precisely because an authorized drug exists, the line between that product and research material has to be drawn carefully — the clinical evidence belongs to the authorized drug under its conditions of use, not to research vials, and no equivalence is implied anywhere on this site. This guide covers the research picture, the Canadian regulatory status, and what to verify before sourcing research-grade material.

The research literature

Beyond the approved indication’s clinical program, tesamorelin appears in the literature in laboratory and preclinical contexts: GHRH-receptor pharmacology and signalling studies, GH-axis regulation models (pulsatile release, IGF-1 axis readouts), and comparative work against other GHRH analogs. Research designs choose it when a stabilized GHRH-receptor agonist with a well-characterised pharmacological profile is required. As with every compound on this site, statements in that literature describe what was measured in studies — they are not claims about research material, and no outcome is implied.

Tesamorelin vs sermorelin, CJC-1295 and ipamorelin

The GH-axis research compounds divide into two classes that are not interchangeable in research designs. GHRH analogs — tesamorelin, sermorelin (the older, unmodified GHRH 1-29 fragment with a short half-life), and CJC-1295 (a differently modified analog) — act at the pituitary GHRH receptor. GH secretagogues such as ipamorelin act at the ghrelin (GHS-R1a) receptor instead. Within the GHRH class, the differences are pharmacokinetic (how each modification stabilises the peptide) and evidentiary (tesamorelin has by far the deepest human literature; sermorelin’s is older; CJC-1295’s is largely preclinical). The full mechanistic comparison across all four compounds lives in our dedicated guide: Sermorelin vs Ipamorelin vs Tesamorelin.

Regulatory status in Canada

Tesamorelin’s Canadian history is specific and worth stating precisely. EGRIFTA — the tesamorelin drug product, developed by the Canadian company Theratechnologies — was previously authorised in Canada under two DINs. Both DINs are now listed as cancelled in Health Canada’s Drug Product Database (one pre-market, one post-market; verified September 2026), and no tesamorelin drug product is currently marketed in Canada. The US prescription product remains approved there for its narrow indication. In Canada today, tesamorelin may be sold only as a research-use-only laboratory chemical — not as a medicine in any form. Our guide to peptide legality in Canada covers the wider framework.

Purity and the COA question

For a research chemical, the meaningful quality question is what is actually in the vial. Quantum publishes a per-batch Certificate of Analysis with HPLC purity (target ≥99%) and mass-spectrometry identity confirmation from an independent Canadian laboratory. The batch number is printed on the vial, the tesamorelin COA is downloadable, and certificates can be verified at the testing lab’s own site — see the certificate of analysis hub for how to read one.

Where to buy tesamorelin in Canada

Quantum Peptides supplies tesamorelin as a standalone 20mg lyophilized research vial, batch-coded and third-party tested, shipping domestically from Edmonton — see the tesamorelin product page for current stock and the batch COA. The supplied format is dry lyophilized peptide that a laboratory reconstitutes for its own protocols; pre-mixed pens sold elsewhere are different preparations. For research use only — not for human consumption. New to sourcing? Start with how to buy research peptides in Canada and how to verify a legit supplier.

Frequently asked questions

Is tesamorelin available in Canada?

Only as a research-use-only laboratory chemical. The former Canadian drug authorizations (EGRIFTA’s two DINs) are listed as cancelled in Health Canada’s Drug Product Database, and no tesamorelin medicine is currently marketed in Canada.

Is tesamorelin the same as EGRIFTA?

EGRIFTA is a prescription drug product whose active ingredient is tesamorelin, approved in the US for one narrow indication under medical supervision. A research vial is not that product and is not represented as interchangeable with it — the clinical evidence belongs to the authorized drug under its conditions of use.

Do you need a prescription for tesamorelin in Canada?

There is no Canadian prescription product to fill — the former authorizations are cancelled. Research-labelled tesamorelin is a laboratory material sold for research use only; it is not a medication in any format and is not for human use.

How is tesamorelin different from sermorelin and CJC-1295?

All three are GHRH analogs, but with different stabilizing modifications and very different evidence bases — tesamorelin has the deepest human clinical literature via its approved US indication. See our full comparison guide.

What is the tesamorelin dosage?

We don’t provide protocols: this material is sold for laboratory research only, and published exposure data is specific to the authorized drug product, not research vials.

Does Quantum’s tesamorelin come with a COA?

Yes — every batch is tested by an independent third-party Canadian laboratory using HPLC and mass spectrometry; the batch-specific COA is downloadable and verifiable at the lab’s own site.

For laboratory research use only. Not for human consumption. Not evaluated for approval by Health Canada. The information on this page summarises regulatory records and published research for educational purposes and is not medical advice.